This market research study identifies CSL Behring, Grifols, Baxalta, Octapharma, and Kedrion as the key players in the global human albumin market. A comprehensive analysis of this market is also presented in terms of application (replacement therapy, drug formulation and delivery, and vaccines) and by geography (Americas, APAC, and EMEA). 

Overview of the human albumin market

According to the human albumin industry analysis, the global human albumin market is anticipated to witness steady growth and will post a CAGR of nearly 5% over the forecast period. Human albumin was initially used only as a volume replacement therapy; however, extensive research has shown that human albumin has numerous applications in other therapeutic areas as well. For instance, Grifols is exploring the use of the product to stabilize Alzheimer’s disease. Moreover, drugs containing human serum albumins, such as Levemir and Abraxane are used to treat diabetes and metastatic breast cancer, respectively. Furthermore, the on-going research and augmented adoption of albumin in the new therapeutic areas will boost this market’s growth during the predicted period.

The development of recombinant albumin is one of the emerging trends likely to propel the human albumin market growth prospects over the next four years. Human serum albumin is obtained from blood plasma, which may be collected from different individuals resulting in the risk of contracting various pathogenic infections. Also, the lack of blood donors limits the quantity of albumin produced. Therefore, the increasing need to produce albumin from alternative sources with fewer side effects led to the use of transgenic expression systems, such as bacterial and yeast expression systems or transgenic insect cells, avian eggs, and plants. This results in the mass production of simple proteins such as albumin by inexpensive methods. Besides this, recombinant albumin is also extracted from cattle milk and by gene expression.

Segmentation by application and analysis of the human albumin market

• Replacement therapy
• Drug formulation and delivery
• Vaccines

The fluid replacement or volume replacement therapy segment is one of the fastest growing sectors of the market as replacement therapy is essential in the treatment of severe anemia. Albumin can be used in the form of a plasma expander during cardiopulmonary bypass surgeries, or for treating sepsis in individuals with liver cirrhosis, burns, or critically ill patients. It is also used to treat hypoalbuminemia and shock. This factor will increase the overall human albumin market revenue.

Geographical segmentation and analysis of the human albumin market

• Americas
• APAC
• EMEA

In terms of geography, the APAC region dominated the global human albumin market and accounted for more than 45% of the market share during 2015. China was the highest revenue contributor because of the increased demand for albumin. A rising patient population and easy availability of drugs will aid in the growth of this market. Moreover, the increased awareness about the therapeutic potential of immunoglobulins is expected to affect the growth of this market in APAC.

Competitive landscape and key vendors

The competition in the global human albumin market is intense due to the presence of several well-established vendors such as CSL, Grifols, Baxalta, Octapharma, Kedrion, and China Biologics. The competitive environment in this market is expected to intensify with an increase in product or service extensions. The competition among the leading players is anticipated to increase as they enter into partnerships or acquire distributors to increase their sales and expand their businesses worldwide.

Key vendors in this market are 

• CSL Behring
• Grifols
• Baxalta
• Octapharma
• Kedrion

Other prominent vendors in the market are AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVitria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, and Yoshitomi.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global human albumin market?
• What are the key market trends impacting the growth of the global human albumin market?
• What are the challenges to market growth?
• Who are the key vendors in the global human albumin market?
• What are the market opportunities and threats faced by the vendors in the global human albumin market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global human albumin market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Women’s Health Market 2016-2020
• Global Plasma Therapeutics Market 2015-2019
• Global Feminine Wipes Market 2016-2020
• Global Fertility Services Market 2016-2020